Medical University of South Carolina - Cancer Center Support Grant

描述（由申请人提供）：霍林斯癌症中心（HCC）在南卡罗来纳州医科大学（MUSC）寻求更新其国家癌症研究所（NCI）指定在2009年通过P30癌症中心支持补助金（CCSG）机制。作为南卡罗来纳州领先的学术医疗中心，MUSC负责建立临床，基础，转化和基于人口的研究计划，以满足该州的重大医疗保健需求。HCC的使命是减少南卡罗来纳州的癌症负担。为了完成这一使命，主任安德鲁·S。卡夫和HCC的高级领导层建立了一个强大的跨学科基础，现在包括来自5个MUSC学院和20个学术部门的122名癌症科学家。 跨学科的创新研究通过将HCC组织为四个项目来推动：癌症基因与分子调节、癌症免疫学、发育癌症治疗学和癌症控制。发现和有效转化研究的快速发展得到了共享研究资源的支持，其中五个在本申请中介绍：脂质组学，细胞评估和治疗，细胞和分子成像，生物储存和组织分析以及生物统计学。HCC还寻求CCSG对其临床试验办公室的支持，该办公室在过去四年中率先将介入治疗试验的应计数量大幅增加了59%。值得注意的是，2012年参与介入治疗试验的患者中有26%是少数民族，这一项目期间增加了45%。这是由HCC领导的渐进式外展服务和对南卡罗来纳州人的癌症教育所推动的，南卡罗来纳州人主要是农村人口，其中包括美国一些医疗服务最不足的人。如今，HCC每年的校外研究资金总额为4080万美元，其中1860万美元来自NCI，自2009年以来分别增长了31%和54%。HCC在第一个项目期间成功地利用了CCSG的资金及其NCI指定的癌症中心地位，以继续该中心的快速发展。在本项目期间，总部合同委员会为该中心的34名战略征聘工作提供了支助。在MUSC，生物工程和药物发现大楼的两个最先进的研究设施的开放，导致了额外的66，156英尺的HCC研究空间，使HCC权限下的校园空间总量达到270，174英尺。自2009年以来，HCC已投资530万美元用于引进尖端技术，并获得了另外380万美元的机构承诺，以增加可用资源的范围。这些令人印象深刻的发展确保了HCC科学家将继续他们在为癌症生物学的理解做出重大贡献方面的模范记录，同时将这些发现与癌症控制，诊断和治疗的新方法的开发相结合。

DESCRIPTION (provided by applicant): The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation awarded in 2009 via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's leading academic medical center, MUSC is charged with building clinical, basic, translational, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in South Carolina. To accomplish this mission, the Director, Dr. Andrew S. Kraft, and the HCC senior leadership have established a robust, interdisciplinary base that now includes 122 cancer scientists from 5 MUSC colleges and 20 academic departments. Interdisciplinary, innovative research is driven through the organization of the HCC into four programs: Cancer Genes & Molecular Regulation, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by shared research resources, five of which are presented in this application: Lipidomics, Cell Evaluation & Therapy, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. The HCC also seeks CCSG support for its Clinical Trials Office which has spear-headed a dramatic 59% increase in accrual volume for interventional treatment trials over the last four years. Notably, 26% of patients enrolled onto interventional treatment trials in 2012 were minorities, representing a 45% increase in this project period. This has been promoted by HCC-led progressive outreach services and cancer education to South Carolinians, a largely rural population that includes some of the most medically underserved people in the US. Today, the HCC has $40.8M in annual total extramural research funding with $18.6M derived from the NCI, representing a 31% and 54% increase, respectively, since 2009. The HCC has successfully leveraged CCSG funding during the first project period and its NCI-designated Cancer Center status to continue the rapid growth of this Center. During the current project period, the HCC supported 34 strategic recruitments to the Center. The opening of two state-of-the-art research facilities at MUSC, the Bioengineering and Drug Discovery Buildings, has resulted in an additional 66,156 ft of HCC research space, bringing the total amount of space on campus under the HCC authority to 270,174 ft. The HCC has invested $5.3M since 2009 to introduce cutting-edge technologies and has secured another $3.8M in institutional commitments to increase the range of available resources. These impressive developments ensure that HCC scientists will continue their exemplary track record in making significant contributions to the understanding of cancer biology while coupling these findings to the development of novel approaches to cancer control, diagnosis, and treatment.